Business Wire

Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives

Share

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, continues its commitment to specialized Centers of Development as it adds two new executives to the team. Christopher Heckman, RN, BSN, joins as the vice president for oncology development and will build the company’s Center of Development in Oncology while Art Wamil, M.D., Ph.D., joins as senior medical director and lead neurologist to further strengthen its Neuro Degenerative and Rare Disease Centers of Development. Since focusing its expertise in five Centers of Development in 2018, Synteract has seen increasing opportunities in its biopharma business, especially in oncology and neuro degenerative areas, coming from both rare disease and non-rare indications.

With 23 years of clinical research experience, Christopher Heckman is an accomplished leader with management, clinical and business development experience. He possesses a broad experience base across the drug development lifecycle, with both strategic and operational lines of responsibility, with hands-on engagement in all development phases as well as global registration experience. Previously, he has held leadership positions for portfolio management with both large and small CROs and managed an oncology product to regulatory approval for a major pharmaceutical company.

Dr. Wamil is a neurologist/electrophysiologist with more than 20 years of scientific and medical experience in the healthcare and biotech/pharmaceutical industries, primarily in neurology, neuroscience/CNS, and diagnostic medicine fields, working with both adults and children. He has co-authored more than 30 scientific papers and over 70 scientific abstracts, posters and presentations, and is an active member of AAN, AES, MDS, AHA/ASA, and AMA.

CEO Steve Powell says, “We are delighted to add these experienced leaders to the organization as they both offer breadth and depth of knowledge in their respective therapeutic areas and a keen understanding of what is needed to move studies through the complex clinical development process. Their years of experience and expansive scientific and medical capabilities will add to our already strong teams. I am confident they will be valuable additions in informing the best strategies for the trials we undertake on our clients’ behalf.”

Dr. Wamil received his M.D. and Ph.D. from Medical University of Lublin (MUL) in Poland and completed his internships, residencies and fellowships at MUL, Vanderbilt University, and Northwestern University/Children’s Memorial Hospital. He trained in electrophysiology/epilepsy and previously served on the faculty in Neurology and Anesthesiology at Vanderbilt University Medical Center for over 10 years.

Mr. Heckman received his Bachelor of Science in Nursing and Organic Chemistry from Misericordia University and completed coursework for an MBA in Finance at the Iacocca Institute at Lehigh University, both in Pennsylvania.

About Synteract

Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. With 800 employees across 21 countries, Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.

Contact information

Beth Walsh
beth@clearpointagency.com
760-230-2424

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Defence Unlimited International Corp. is Hiring Veterans17.7.2019 20:58:00 CESTPress release

Defence Unlimited International is one of the fastest growing companies operating within the defence and security space. Defence Unlimited International has adopted a unique outsourced model which integrates multiple partners both individual and corporate, on its projects. This has enabled it to offer and deliver to its clients best of breed bespoke solutions. Whilst Defence Unlimited is pursuing its drive towards achieving a more global footprint in its operations, the founder, Edward Banayoti firmly reiterates the continued commitment of the company to its existing strategy of identifying and successfully deploying experienced individuals that have served in the military. Individuals and teams with such experience can offer invaluable value added within projects Defence Unlimited are active in or are in the process of executing. "We take pride in our track record of offering numerous opportunities to Veterans who have served their country, giving such individuals who have heeded a pa

Gartner Names Airship a Leader, Positioned Highest in Execution and Furthest in Vision in the Magic Quadrant for Mobile Marketing Platforms17.7.2019 15:59:00 CESTPress release

Customer engagement company Airship today announced that it has been named a Leader by Gartner, Inc. in its 2019 Magic Quadrant for Mobile Marketing Platforms1. Among 18 vendors evaluated, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision. A complimentary copy of the full report is available from Airship. “We believe Gartner’s positioning of Airship validates our unique ability to deliver innovative, transformative digital customer experiences for the world’s leading brands,” said Brett Caine, CEO and president, Airship. “Airship delivers rich messages with pinpoint accuracy on whatever channel is most convenient and effective for the customer. Today’s customer expects proactive information and real-time response, and Airship is the essential component that makes it all possible.” According to Gartner, “Globally, consumers spend more of their time on smartphones than on desktops, laptops or tablets. This broad and rapid consumer a

GSMA Signs £38 Million Funding Partnership With the Department of International Development17.7.2019 15:02:00 CESTPress release

The GSMA today announced that it has signed a thirty-eight million-pound partnership with the UK’s Department for International Development (DFID). The ‘Partnership for Inclusion, Innovation and Scale’ will provide funding for the GSMA’s Mobile for Development work on digital inclusion, digital identity, energy, water, sanitation and the reduction of the mobile gender gap. It will also include two new areas of focus: disability and climate. “This landmark partnership with DFID reinforces the joint power and potential of the private and public sectors working together and ensures that we will continue our crucial role of stimulating digital innovation to deliver both sustainable business and large-scale socio-economic impact for the underserved,” said Mats Granryd, Director General, GSMA. “This project reinforces our commitment to supporting the UN’s Sustainable Development Goals and using the power of technology to reduce global inequalities.” Inclusion, Innovation and Scale The partne

Gilead Sciences Announces Changes to Senior Leadership Team17.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function. Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization. “Gregg has been a valued leader at Gilead for nearly 20

Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company17.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation. “Over the past nine years, John’s scientific contributions and le